Shinsuke Maruyama
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Shinsuke Maruyama has a total of 122 co-authors. Here are the top co-authors by number of shared publications:
Yoshifumi Kawano
Department of Pediatrics, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan
3 shared publications- Akira Ohtake
Affiliations Department of Pediatrics, Saitama Medical University Hospital, Moroyama, Japan, Department of Clinical Genomics, Saitama Medical University Hospital, Moroyama, Japan
2 shared publications - Hideo Sasai
Department of Pediatrics, Graduate School of Medicine, Gifu University
2 shared publications - Hirofumi Komaki
Translational Medical Center, National Center of Neurology and Psychiatry, Tokyo, Japan
2 shared publications - Kentaro Ueno
Department of Pediatrics Kagoshima University Hospital Kagoshima Japan
2 shared publications Yasuhiro Okamoto
Department of Pediatrics Graduate School of Medical and Dental Sciences Kagoshima University Kagoshima JPN
2 shared publications
Latest Publications
- Open Access
- 31 March 2026
- Published by Elsevier in Biochemistry and Biophysics Reports
- Vol. 46, 102569
Quantification of glycosaminoglycans in dried blood spots, and evaluation of its usefulness as a secondary newborn screening test for mucopolysaccharidoses
- 31 March 2026
- Published by Elsevier in Biochemistry and Biophysics Reports
- Vol. 46, 102569
Open AccessQuantification of glycosaminoglycans in dried blood spots, and evaluation of its usefulness as a secondary newborn screening test for mucopolysaccharidoses
- Open Access
- 19 September 2025
- Published by Springer Nature in Cureus
- Vol. 17 (9)
Administration of Onasemnogene Abeparvovec in an Infant With Spinal Muscular Atrophy and PCR-Confirmed SARS-CoV-2 Infection
Onasemnogene abeparvovec (OA) is used to treat spinal muscular atrophy (SMA), and early treatment is critical. However, OA administration may trigger an immune response. To date, no studies have established the optimal timing for OA administration following SARS-CoV-2 infection. We report the case of an eight-month-old female infant presenting with delayed motor development who was diagnosed with SMA. OA therapy was initially prescribed but postponed because of a risk of COVID-19 exposure; the patient’s mother had recently developed COVID-19. Despite testing positive for SARS-CoV-2, the infant remained asymptomatic, and her viral load did not increase. OA was administered 19 days after the mother’s COVID-19 diagnosis. The patient did not develop COVID-19 and experienced no significant adverse effects. This case suggests that OA administration may be safe in asymptomatic SARS-CoV-2-positive patients with low viral loads, allowing timely therapy to preserve motor function. Further studies are needed to establish evidence-based guidelines for the optimal timing of OA administration.
- 19 September 2025
- Published by Springer Nature in Cureus
- Vol. 17 (9)
Open AccessAdministration of Onasemnogene Abeparvovec in an Infant With Spinal Muscular Atrophy and PCR-Confirmed SARS-CoV-2 Infection
Onasemnogene abeparvovec (OA) is used to treat spinal muscular atrophy (SMA), and early treatment is critical. However, OA administration may trigger an immune response. To date, no studies have established the optimal timing for OA administration following SARS-CoV-2 infection. We report the case of an eight-month-old female infant presenting with delayed motor development who was diagnosed with SMA. OA therapy was initially prescribed but postponed because of a risk of COVID-19 exposure; the patient’s mother had recently developed COVID-19. Despite testing positive for SARS-CoV-2, the infant remained asymptomatic, and her viral load did not increase. OA was administered 19 days after the mother’s COVID-19 diagnosis. The patient did not develop COVID-19 and experienced no significant adverse effects. This case suggests that OA administration may be safe in asymptomatic SARS-CoV-2-positive patients with low viral loads, allowing timely therapy to preserve motor function. Further studies are needed to establish evidence-based guidelines for the optimal timing of OA administration.
- 1 January 2025
- Published by Wiley in Pediatrics International
- Vol. 67 (1) , e70264
Resolution of brady‐ and tachyarrhythmias with everolimus in a child with tuberous sclerosis complex: A case report
- 1 January 2025
- Published by Wiley in Pediatrics International
- Vol. 67 (1) , e70264
Resolution of brady‐ and tachyarrhythmias with everolimus in a child with tuberous sclerosis complex: A case report
- 15 May 2024
- Published by Elsevier in Pediatric Neurology
- Vol. 157, 29-38
Infantile Epileptic Spasms Syndrome Complicated by Leigh Syndrome and Leigh-Like Syndrome: A Retrospective, Nationwide, Multicenter Case Series
- 15 May 2024
- Published by Elsevier in Pediatric Neurology
- Vol. 157, 29-38
Infantile Epileptic Spasms Syndrome Complicated by Leigh Syndrome and Leigh-Like Syndrome: A Retrospective, Nationwide, Multicenter Case Series
- Open Access
Systemic administration of the antisense oligonucleotide NS-089/NCNP-02 for skipping of exon 44 in patients with Duchenne muscular dystrophy: study protocol for a phase I/II clinical trial
Aim The purpose of this study is to evaluate the safety and pharmacokinetics of the novel morpholino oligomer NS-089/NCNP-02 which can induce exon 44 skipping, in patients with DMD. Additionally, we aimed to identify markers predictive of therapeutic efficacy and determine the optimal dosing for future studies. Methods This is an open-label, dose-escalation, two-center phase I/II trial in ambulant patients with DMD, presence of an out-of-frame deletion, and a mutation amenable to exon 44 skipping. Part 1 is a stepwise dose-finding stage (4 weeks) during which NS-089/NCNP-02 will be administered intravenously at four dose levels once weekly (1.62, 10, 40, and 80 mg/kg); Part 2 is a 24-week evaluation period based on the dosages determined during Part 1. The primary (safety) endpoints are the results of physical examinations, vital signs, 12-lead electrocardiogram and echocardiography tests, and adverse event reporting. Secondary endpoints include expression of dystrophin protein, motor function assessment, exon 44 skipping efficiency, plasma and urinary NS-089/NCNP-02 concentrations, and changes in blood creatine kinase levels. Discussion Exon-skipping therapy using ASOs shows promise in selected patients, and this first-in-human study is expected to provide critical information for subsequent clinical development of NS-089/NCNP-02.
Open AccessSystemic administration of the antisense oligonucleotide NS-089/NCNP-02 for skipping of exon 44 in patients with Duchenne muscular dystrophy: study protocol for a phase I/II clinical trial
Aim The purpose of this study is to evaluate the safety and pharmacokinetics of the novel morpholino oligomer NS-089/NCNP-02 which can induce exon 44 skipping, in patients with DMD. Additionally, we aimed to identify markers predictive of therapeutic efficacy and determine the optimal dosing for future studies. Methods This is an open-label, dose-escalation, two-center phase I/II trial in ambulant patients with DMD, presence of an out-of-frame deletion, and a mutation amenable to exon 44 skipping. Part 1 is a stepwise dose-finding stage (4 weeks) during which NS-089/NCNP-02 will be administered intravenously at four dose levels once weekly (1.62, 10, 40, and 80 mg/kg); Part 2 is a 24-week evaluation period based on the dosages determined during Part 1. The primary (safety) endpoints are the results of physical examinations, vital signs, 12-lead electrocardiogram and echocardiography tests, and adverse event reporting. Secondary endpoints include expression of dystrophin protein, motor function assessment, exon 44 skipping efficiency, plasma and urinary NS-089/NCNP-02 concentrations, and changes in blood creatine kinase levels. Discussion Exon-skipping therapy using ASOs shows promise in selected patients, and this first-in-human study is expected to provide critical information for subsequent clinical development of NS-089/NCNP-02.
- 1 February 2022
- Published by Elsevier in Pediatric Neurology
- Vol. 127, 48-55
Prolonged Video-EEG and Heart Rate Variability can Elucidate Autonomic Dysregulation in Infantile Apneic Seizures
- 1 February 2022
- Published by Elsevier in Pediatric Neurology
- Vol. 127, 48-55
Prolonged Video-EEG and Heart Rate Variability can Elucidate Autonomic Dysregulation in Infantile Apneic Seizures
- 19 January 2020
- Published by Wiley in Pediatrics International
- Vol. 62 (1) , 96-97
Right‐ventricular outflow tract obstruction by adrenocorticotrophic hormone therapy for infantile spasms after Norwood operation
- 19 January 2020
- Published by Wiley in Pediatrics International
- Vol. 62 (1) , 96-97
Right‐ventricular outflow tract obstruction by adrenocorticotrophic hormone therapy for infantile spasms after Norwood operation
- Open Access
- 1 June 2017
- Published by Elsevier in Molecular Genetics and Metabolism Reports
- Vol. 11, 69-71
A surviving 24-month-old patient with neonatal-onset carnitine palmitoyltransferase II deficiency
- 1 June 2017
- Published by Elsevier in Molecular Genetics and Metabolism Reports
- Vol. 11, 69-71
Open AccessA surviving 24-month-old patient with neonatal-onset carnitine palmitoyltransferase II deficiency
- 1 November 2016
- Published by Elsevier in Brain and Development
- Vol. 38 (10) , 947-949
Immunoglobulin A deficiency following treatment with lamotrigine
- 1 November 2016
- Published by Elsevier in Brain and Development
- Vol. 38 (10) , 947-949
Immunoglobulin A deficiency following treatment with lamotrigine